Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H34F3N5O3 |
| Molecular Weight | 521.5751 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](CO)NC1=NC(=CC(=C1)C2=CC(NC(=O)N3CC[C@@H](CC(F)(F)F)C3)=CC=C2C)N4CCOCC4
InChI
InChIKey=GZMYLSJUNSCMTD-MOPGFXCFSA-N
InChI=1S/C26H34F3N5O3/c1-17-3-4-21(31-25(36)34-6-5-19(15-34)14-26(27,28)29)13-22(17)20-11-23(30-18(2)16-35)32-24(12-20)33-7-9-37-10-8-33/h3-4,11-13,18-19,35H,5-10,14-16H2,1-2H3,(H,30,32)(H,31,36)/t18-,19+/m1/s1
| Molecular Formula | C26H34F3N5O3 |
| Molecular Weight | 521.5751 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 11:36:48 GMT 2025
by
admin
on
Wed Apr 02 11:36:48 GMT 2025
|
| Record UNII |
2VPX8HL8AB
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
156297592
Created by
admin on Wed Apr 02 11:36:48 GMT 2025 , Edited by admin on Wed Apr 02 11:36:48 GMT 2025
|
PRIMARY | |||
|
12241
Created by
admin on Wed Apr 02 11:36:48 GMT 2025 , Edited by admin on Wed Apr 02 11:36:48 GMT 2025
|
PRIMARY | |||
|
2VPX8HL8AB
Created by
admin on Wed Apr 02 11:36:48 GMT 2025 , Edited by admin on Wed Apr 02 11:36:48 GMT 2025
|
PRIMARY | |||
|
C180835
Created by
admin on Wed Apr 02 11:36:48 GMT 2025 , Edited by admin on Wed Apr 02 11:36:48 GMT 2025
|
PRIMARY | |||
|
2639957-39-2
Created by
admin on Wed Apr 02 11:36:48 GMT 2025 , Edited by admin on Wed Apr 02 11:36:48 GMT 2025
|
PRIMARY | |||
|
300000039591
Created by
admin on Wed Apr 02 11:36:48 GMT 2025 , Edited by admin on Wed Apr 02 11:36:48 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
In contrast to approved therapies targeting Class I V600E BRAF mutant tumors, KIN-2787 was active across all classes of BRAF-altered melanoma cells.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
KIN-2787 is a potent and selective pan-RAF inhibitor that was designed to be effective in all classes of BRAF alterations by targeting mutant BRAF monomers and RAF dimers, regardless of isoform. Furthermore, the pharmacokinetic properties of KIN-2787 allow sustained target coverage, thus minimizing paradoxical activation.
|